Plus Therapeutics presents interim ReSPECT-LM phase 1 data

Plus Therapeutics g targeted radiotherapeutics with advanced platform technologies for central nervous system, CNS, cancers, presented data in a podium presentation updating the progress of its ReSPECT-LM clinical trial of Rhenium Obisbemeda in leptomeningeal disease. The data were presented at the 2024 Society for NeuroOncology/American Society for Clinical Oncology, ASCO, CNS Metastases Conference August 8-10, 2024 in Denver, Colorado. The presentation, titled, “Phase 1 Dose Escalation of Rhenium Obisbemeda for the Treatment of Leptomeningeal Metastases: Ongoing Clinical Study Update for Initial Safety and Feasibility,” provided a safety and efficacy update on the single dose trial for the first 4 cohorts. The trial is currently enrolling in Cohort 5. The study was presented by Andrew Brenner, M.D., Ph.D., Professor and Kolitz/Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, San Antonio.